Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

118 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Disruption of PH-kinase domain interactions leads to oncogenic activation of AKT in human cancers.
Parikh C, Janakiraman V, Wu WI, Foo CK, Kljavin NM, Chaudhuri S, Stawiski E, Lee B, Lin J, Li H, Lorenzo MN, Yuan W, Guillory J, Jackson M, Rondon J, Franke Y, Bowman KK, Sagolla M, Stinson J, Wu TD, Wu J, Stokoe D, Stern HM, Brandhuber BJ, Lin K, Skelton NJ, Seshagiri S. Parikh C, et al. Among authors: seshagiri s. Proc Natl Acad Sci U S A. 2012 Nov 20;109(47):19368-73. doi: 10.1073/pnas.1204384109. Epub 2012 Nov 7. Proc Natl Acad Sci U S A. 2012. PMID: 23134728 Free PMC article.
Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib.
Eberhard DA, Johnson BE, Amler LC, Goddard AD, Heldens SL, Herbst RS, Ince WL, Jänne PA, Januario T, Johnson DH, Klein P, Miller VA, Ostland MA, Ramies DA, Sebisanovic D, Stinson JA, Zhang YR, Seshagiri S, Hillan KJ. Eberhard DA, et al. Among authors: seshagiri s. J Clin Oncol. 2005 Sep 1;23(25):5900-9. doi: 10.1200/JCO.2005.02.857. Epub 2005 Jul 25. J Clin Oncol. 2005. PMID: 16043828 Clinical Trial.
Somatic mutations lead to an oncogenic deletion of met in lung cancer.
Kong-Beltran M, Seshagiri S, Zha J, Zhu W, Bhawe K, Mendoza N, Holcomb T, Pujara K, Stinson J, Fu L, Severin C, Rangell L, Schwall R, Amler L, Wickramasinghe D, Yauch R. Kong-Beltran M, et al. Among authors: seshagiri s. Cancer Res. 2006 Jan 1;66(1):283-9. doi: 10.1158/0008-5472.CAN-05-2749. Cancer Res. 2006. PMID: 16397241
Oncogenic BRAF is required for tumor growth and maintenance in melanoma models.
Hoeflich KP, Gray DC, Eby MT, Tien JY, Wong L, Bower J, Gogineni A, Zha J, Cole MJ, Stern HM, Murray LJ, Davis DP, Seshagiri S. Hoeflich KP, et al. Among authors: seshagiri s. Cancer Res. 2006 Jan 15;66(2):999-1006. doi: 10.1158/0008-5472.CAN-05-2720. Cancer Res. 2006. PMID: 16424035
Regulation of ERK3/MAPK6 expression by BRAF.
Hoeflich KP, Eby MT, Forrest WF, Gray DC, Tien JY, Stern HM, Murray LJ, Davis DP, Modrusan Z, Seshagiri S. Hoeflich KP, et al. Among authors: seshagiri s. Int J Oncol. 2006 Oct;29(4):839-49. Int J Oncol. 2006. PMID: 16964379
Distinguishing cancer-associated missense mutations from common polymorphisms.
Kaminker JS, Zhang Y, Waugh A, Haverty PM, Peters B, Sebisanovic D, Stinson J, Forrest WF, Bazan JF, Seshagiri S, Zhang Z. Kaminker JS, et al. Among authors: seshagiri s. Cancer Res. 2007 Jan 15;67(2):465-73. doi: 10.1158/0008-5472.CAN-06-1736. Cancer Res. 2007. PMID: 17234753
118 results